SAGE Therapeutics (NASDAQ:SAGE): Canaccord Genuity Reiterates Buy Rating Today, Has a Target of $220.0000/Share

June 13, 2018 - By Kurt Siggers

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Investors sentiment increased to 1.73 in 2018 Q1. Its up 0.24, from 1.49 in 2017Q4. It is positive, as 22 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 47 funds opened positions while 88 raised stakes. 45.19 million shares or 9.02% more from 41.45 million shares in 2017Q4 were reported.

Rmb Capital Mngmt Ltd Liability Com invested in 19,988 shares. Sei Company accumulated 5 shares. Goldman Sachs Group stated it has 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Public Employees Retirement Association Of Colorado reported 0% stake. Indiana-based University Of Notre Dame Du Lac has invested 0.97% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Oak Ridge Ltd reported 279,659 shares. Ameritas Investment Ptnrs has 3,534 shares for 0.03% of their portfolio. Balyasny Asset Management Ltd Com stated it has 0.16% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Moreover, Cutter Brokerage has 0.34% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Swiss Retail Bank, a Switzerland-based fund reported 79,400 shares. Fincl Bank Of America Corporation De has 87,289 shares. Manufacturers Life Communication The holds 31,067 shares. California Employees Retirement Systems owns 69,665 shares or 0.02% of their US portfolio. Emory University has invested 1.86% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Bluecrest Capital Mngmt owns 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 2,147 shares.

Since December 14, 2017, it had 0 insider purchases, and 5 selling transactions for $32.85 million activity. Another trade for 28,153 shares valued at $4.02M was made by IGUCHI KIMI on Monday, April 23. On Wednesday, January 10 Kanes Stephen sold $7.80M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 44,000 shares. Another trade for 59,000 shares valued at $9.96 million was sold by STARR KEVIN P. Another trade for 7,000 shares valued at $1.08 million was sold by FRATES JAMES M. Robichaud Albert sold $9.57M worth of stock.

SAGE Therapeutics (NASDAQ:SAGE) Rating Reaffirmed

New York: In a report sent to investors on Tuesday, 12 June, Canaccord Genuity reaffirmed their Buy rating on SAGE Therapeutics (NASDAQ:SAGE) shares. They now have a $220.0000 target price per share on the firm. Canaccord Genuity’s target indicates a potential upside of 29.78 % from the company’s close price.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 7 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics has $277.0 highest and $20300 lowest target. $224.71’s average target is 32.56% above currents $169.52 stock price. SAGE Therapeutics had 8 analyst reports since January 31, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, March 26 by Canaccord Genuity. The stock has “Buy” rating by SunTrust on Tuesday, February 27. On Wednesday, January 31 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by BMO Capital Markets on Monday, April 23. Chardan Capital Markets upgraded the shares of SAGE in report on Tuesday, May 22 to “Buy” rating. The rating was maintained by RBC Capital Markets on Thursday, February 22 with “Buy”.

The stock decreased 3.55% or $6.24 during the last trading session, reaching $169.52. About 1.07M shares traded or 130.90% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 127.92% since June 13, 2017 and is uptrending. It has outperformed by 115.35% the S&P500.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 EPS, up 0.53 % or $0.01 from last year’s $-1.88 per share. After $-1.68 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31 % negative EPS growth.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.89 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: which released: “10 Biggest Price Target Changes For Wednesday” on June 13, 2018, also with their article: “Here’s Why Sage Therapeutics Rose as Much as 20.3% Today” published on June 12, 2018, published: “Stocks end modestly higher as investors await Fed rate decision” on June 12, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: and their article: “Pre-Open Movers 06/12: (GLMD) (RH) (PLAY) Higher; (IDRA) (JCAP) (IMMU) Lower (more…)” published on June 12, 2018 as well as‘s news article titled: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” with publication date: June 04, 2018.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: